Treatment progress of gastrointestinal stromal tumor / 中华胃肠外科杂志
Chinese Journal of Gastrointestinal Surgery
;
(12): 292-296, 2013.
Article
Dans Chinois
| WPRIM
| ID: wpr-314805
ABSTRACT
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Its pathogenesis is defined by mutations within the KIT and PDGFRα gene. Surgical resection is the only radical treatment at present, but recurrence is common. In recent years, targeted therapy with imatinib mesylate, which inhibits KIT kinase activity, represents the other cornerstone for the treatment of GIST. For resectable GIST, operation combined with neoadjuvant and adjuvant therapy with imatinib mesylate or other tyrosine kinase inhibitors can improve the prognosis of high-risk patients before or after complete resection. For unresectable GIST, targeted therapy with imatinib mesylate can effectively inhibit and ameliorate the progression of GIST.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Pipérazines
/
Pyrimidines
/
Chirurgie générale
/
Thérapeutique
/
Benzamides
/
Utilisations thérapeutiques
/
Tumeurs stromales gastro-intestinales
/
Traitement médicamenteux
/
Mésilate d'imatinib
/
Tumeurs gastro-intestinales
Limites du sujet:
Humains
langue:
Chinois
Texte intégral:
Chinese Journal of Gastrointestinal Surgery
Année:
2013
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS